Table 1. Clinical characteristics of patients in the four randomised arms.

	Standard AC	Accelerated AC	Standard EC	Accelerated EC
All Patients	N (%)	N (%)	N (%)	N (%)
Patients:	42	42	19	23
Adjuvant	23 (55)	19 (45)	19 (100)	23 (100)
Neoadjuvant	19 (45)	23 (55)
Age: Median (Range)	48 (33–68)	50 (28–67)	50 (35–68)	56 (31–66)
Menopausal status:
Pre	21 (50)	18 (43)	12 (63)	7 (37)
Peri	1 (2)	7 (17)	0	1 (5)
Post	17 (41)	12 (29)	5 (26)	12 (63)
Hysterectomy	3 (7)	5 (12)	2 (11)	3 (16)
Receptor status:
ER/PR (+), HER2 (+)	4 (10)	5 (12)	2 (11)	3 (13)
ER/PR (+), HER2 (−)	13 (31)	20 (48)	11 (58)	10 (43)
ER (+), PR (−), HER2 (+)	3 (7)	1 (2)	0	0
ER (+), PR (−), HER2 (−)	5 (12)	3 (7)	0	2 (9)
ER (−), PR (+), HER2 (+)	1 (2)	0	0	1 (4)
ER (−), PR (+), HER2 (−)	1 (2)	0	0	0
ER/PR (−), HER2 (+)	2 (5)	3 (7)	3 (16)	0
ER/PR (−), HER2 (−)	11 (26)	10 (24)	2 (11)	7 (30)
	N=2 (5%), ER (+on biopsy/−excision), PR/HER2 (−)		N=1 (5%), ER/PR (−), HER2 not known
Pathology (pretreatment):
Infiltrating ductal	36 (86)	36 (86)	16 (84)	19 (83)
Infiltrating lobular	5 (12)	5 (12)	2 (11)	4 (17)
Other	1 (2)	1 (2)	1 (5)	0
Grade:
I	0	2 (5)	1 (5)	1 (4)
II	18 (43)	21 (50)	9 (47)	7 (30)
III	24 (57)	18 (43)	9 (47)	15 (65)
Not known	0	1 (2)	0	0
Vascular invasion:
Positive	6 (14)	5 (12)	4 (21)	2 (9)
Negative	31 (74)	29 (69)	15 (79)	21 (91)
Not known	5 (12)	8 (19)	0	0
Pathology – adjuvant patients only
Pathological size (cm):	1.6 (0.7-5.0)	2.1 (.38-5.4)	1.7 (1.0-6.5)	1.9 (1.2-9.0)
Nodal status:
Positive	3 (13)	6 (32)	2 (11)	6 (26)
Negative	20 (87)	16 (84)	17 (90)	17 (74)
Not done	0	1 (5)	0	0